The Medicare Advantage and Part D programs are a success when measured on metrics such as marketplace competition, consumer satisfaction and quality of care, but could be improved in a number of areas as part of continuous efforts to advance health care quality, health outcomes and health system efficiency, AHA Executive Vice President Tom Nickels told the Centers for Medicare & Medicaid Services yesterday in response to the agency’s request for information on how the programs might be improved. Specifically, AHA encouraged the agency to clarify program guidance for plans and providers in a timely manner; pay quality bonus payments irrespective of the benchmark cap; expand access to telehealth services; and allow plans to adapt benefits to the unique needs of some enrollees. In addition, AHA supports allowing plans to offer non-medical social services; adjusting the Hierarchical Condition Categories for sociodemographic factors; integrating hospice services; and extending access to special needs plans. The letter also offers policy recommendations to address high and rising prices for Part D drugs.

Perspective
Public
Approximately 35 million Americans are enrolled in Medicare Advantage plans in 2026, and that number is expected to grow to about 45 million MA enrollees by…
Headline
The Centers for Medicare & Medicaid Services has released details on downloading its upcoming fiscal year 2025 Program for Evaluating Payment Patterns…
Headline
The Department of Health and Human Services Administration for Community Living has launched the first phase of its Health at Home Challenge, a competition to…
Headline
The AHA shared the following statement with the media in response to a report released May 7 by Families USA.   “This report is long on rhetoric and…
Headline
The AHA May 7 wrote to House and Senate lawmakers in support of the Medicare Advantage Improvement Act (H.R. 8375/S. 4384), bipartisan and bicameral…
Headline
The Centers for Medicare & Medicaid Services announced May 6 that it will provide access to certain glucagon-like peptide-1 (GLP-1) medications to eligible…